Oncology In Vivo Data Integration for Hypothesis Generation

More Information | Back to archive
Full Text of this article Full article [PDF] (769,89 kB)
doi doi:10.2390/biecoll-jib-2012-193
submission May 16, 2012
published July 09, 2012
NCBI PubMed PubMed ID 22773158

Jia Wei and Ming Chen

Correspondence should be addressed to:
Jia Wei
AstraZeneca Innovation Center China, R&D Information China, Building 7, No.898 Halei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China
moc.acenezartsa@nulliew.ynnej


Abstract

AstraZeneca’s Oncology in vivo data integration platform brings multidimensional data from animal model efficacy, pharmacokinetic and pharmacodynamic data to animal model profiling data and public in vivo studies. Using this platform, scientists can cluster model efficacy and model profiling data together, quickly identify responder profiles and correlate molecular characteristics to pharmacological response. Through meta-analysis, scientists can compare pharmacology between single and combination treatments, between different drug scheduling and administration routes.

Reference

Jia Wei and Ming Chen. Oncology In Vivo Data Integration for Hypothesis Generation. Journal of Integrative Bioinformatics, 9(2):193, 2012. Online Journal: http://journal.imbio.de/index.php?paper_id=193
imprint | sitemap | credits | top